Skip to main content

Advertisement

Table 1 Baseline Factors for Patients Initiating HAART in the Natural History Study

From: Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study

Characteristic Total
(n = 2327)
Early Initiation Era
(n = 1631)
Late Initiation Era
(n = 696)
P valueb
Demographics     
   Age at HIV Diagnosis, years 30.1 ± 8.1 29.8 ± 7.9 30.8 ± 8.6 0.007
   Age at HAART initiation, years 34.7 ± 8.6 35.0 ± 8.2 34.1 ± 9.5 0.025
   Female 221 (9.5%) 169 (10.4%) 52 (7.5%) 0.029
   Race/ethnicity     0.188
European American 1024 (44.0%) 730 (44.8%) 294 (42.2%)  
African American 1021 (43.9%) 717 (44.0%) 304 (43.7%)  
Hispanic 194 (8.3%) 130 (8.0%) 64 (9.2%)  
Other 88 (3.8%) 54 (3.3%) 34 (4.9%)  
   Rank of Officer/Warrant at study enrollment 213 (9.9%) 143 (9.4%) 70 (10.1%) 0.606
   Active Duty at HAART initiation 1293 (55.6%) 773 (47.4%) 520 (74.7%) <0.001
Medical History (prior to HAART Initiation)     
   Year of HIV Diagnosis 1994 ± 5.9 1992 ± 4.2 2000 ± 5.1 <0.001
   HIV Diagnosis to HAART initiation, months 44.2 (5.7 - 95.2) 60.9 (16.9 - 103.8) 10.1 (2.0 - 45.5) <0.001
   Nadir CD4+ to HAART initiation, months 3.3 (0.4 - 16.3) 6.5 (0.7 - 19.4) 0.8 (0.2 - 3.7) <0.001
   Seroconverters (SC)a 1691 (72.7%) 1106 (67.8%) 585 (84.1%) <0.001
   Estimated date of SC to HIV Diagnosis, months 8.1 (5.0 - 13.7) 8.4 (5.3 - 14.4) 7.4 (5.0 - 13.7) 0.010
   Viral Load at HAART initiation, log10 copies/mL 4.3 ± 1.0 4.3 ± 1.0 4.4 ± 0.9 <0.001
   CD4+ at HIV Diagnosis, cells/mL 499.7 ± 248.0 524.0 ± 252.1 448.0 ± 231.0 <0.001
   CD4+ nadir, cells/mL 283.2 ± 174.0 276.4 ± 183.3 299.6 ± 148.1 0.005
   CD4+ at HAART Initiation, cells/mL 342.8 ± 211.6 341.0 ± 223.4 346.6 ± 184.8 0.590
<200 459 (24.4%) 357 (28.0%) 102 (16.7%) <0.001
200-349 581 (30.8%) 331 (26.0%) 250 (40.9%)  
350+ 845 (44.8%) 586 (46.0%) 259 (42.4%)  
   Prior AIDS-Defining Event 277 (11.9%) 231 (14.2%) 46 (6.6%) <0.001
   Chronic Hepatitis B co-infection 128 (6.1%) 110 (7.4%) 18 (2.9%) <0.001
   Hepatitis C co-infection 121 (6.1%) 99 (7.1%) 22 (3.6%) 0.002
   Prior Sexually Transmitted Infections (STI) 1058 (45.5%) 839 (51.4%) 219 (31.5%) <0.001
   ARV Use (mono- or dual-therapy) 1224 (52.6%) 1121 (68.7%) 103 (14.8%) <0.001
   Hemoglobin, g/dL 14.1 ± 1.6 13.9 ± 1.6 14.4 ± 1.4 <0.001
   ALT, μ/L 47.1 ± 53.7 48.2 ± 52.9 45.1 ± 55.2 0.336
   Creatinine, mg/dL 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.2 <0.001
Initial HAART Regimen     
   Unboosted PI 1320 (56.7%) 1261 (77.3%) 59 (8.5%) <0.001
   Boosted PI 205 (8.8%) 121 (7.4%) 84 (12.1%)  
   NNRTI 622 (26.7%) 169 (10.4%) 453 (65.1%)  
   PI + NNRTI + NRTI 86 (3.7%) 71 (4.4%) 15 (2.2%)  
   3 NRTI 94 (4.0%) 9 (0.6%) 85 (12.2%)  
  1. Median (IQR) is presented for duration factors given in months
  2. a Percentage of patients who are known seroconverters
  3. b Late versus Early HAART initiation era